$VXRT has positioned themselves really well as a second generation oral vaccine that can fill in the gaps of these more fragile injectables like $PFE and $MRNA.

This new article has @CEPIvaccines Second Wave funding written all over it.
$VXRT has positioned themselves really well as a second generation oral vaccine that can fill in the gaps of these more fragile injectables like $PFE and $MRNA. This new article has @CEPIvaccines Second Wave funding written all over it.
$VXRT has positioned themselves really well as a second generation oral vaccine that can fill in the gaps of these more fragile injectables like $PFE and $MRNA. This new article has @CEPIvaccines Second Wave funding written all over it.
$VXRT has positioned themselves really well as a second generation oral vaccine that can fill in the gaps of these more fragile injectables like $PFE and $MRNA. This new article has @CEPIvaccines Second Wave funding written all over it.
For those unfamiliar with the $VXRT oral vaccine, this “mucosal immunity” (coupled with a strong T-Cell response) is precisely what their target is. Exciting times ahead.
For those unfamiliar with the $VXRT oral vaccine, this “mucosal immunity” (coupled with a strong T-Cell response) is precisely what their target is. Exciting times ahead.
For those unfamiliar with the $VXRT oral vaccine, this “mucosal immunity” (coupled with a strong T-Cell response) is precisely what their target is. Exciting times ahead.
Here are some slides from a recent $VXRT presentation detailing how their oral vaccine tablet (wrapping up Phase 1 trials this month) is aiming for mucosal immunity and is already showing a strong T-cell response.
Here are some slides from a recent $VXRT presentation detailing how their oral vaccine tablet (wrapping up Phase 1 trials this month) is aiming for mucosal immunity and is already showing a strong T-cell response.
Here are some slides from a recent $VXRT presentation detailing how their oral vaccine tablet (wrapping up Phase 1 trials this month) is aiming for mucosal immunity and is already showing a strong T-cell response.
Here are some slides from a recent $VXRT presentation detailing how their oral vaccine tablet (wrapping up Phase 1 trials this month) is aiming for mucosal immunity and is already showing a strong T-cell response.
Here are some slides from a recent $VXRT presentation detailing how their oral vaccine tablet (wrapping up Phase 1 trials this month) is aiming for mucosal immunity and is already showing a strong T-cell response.
Moncef Slaoui, head of the Operation Warp Speed program, just referred to an oral vaccine as the “holy grail” and then mentioned that they are awaiting Phase 1 results from the $VXRT oral vaccine study.

That study wraps up on Dec 10th, FYI.
Moncef Slaoui, head of the Operation Warp Speed program, just referred to an oral vaccine as the “holy grail” and then mentioned that they are awaiting Phase 1 results from the $VXRT oral vaccine study. That study wraps up on Dec 10th, FYI.
Moncef Slaoui, head of the Operation Warp Speed program, just referred to an oral vaccine as the “holy grail” and then mentioned that they are awaiting Phase 1 results from the $VXRT oral vaccine study. That study wraps up on Dec 10th, FYI.
Moncef Slaoui, head of the Operation Warp Speed program, just referred to an oral vaccine as the “holy grail” and then mentioned that they are awaiting Phase 1 results from the $VXRT oral vaccine study. That study wraps up on Dec 10th, FYI.
Both Moderna’s and Pfizer’s vaccines requires a 2nd injection several weeks after the first in order to achieve immunity.

But what happens if millions of people (reluctantly) get the first injection, experience flu-like side effects, and then simply don’t return for the second?
Both Moderna’s and Pfizer’s vaccines requires a 2nd injection several weeks after the first in order to achieve immunity. But what happens if millions of people (reluctantly) get the first injection, experience flu-like side effects, and then simply don’t return for the second?
Both Moderna’s and Pfizer’s vaccines requires a 2nd injection several weeks after the first in order to achieve immunity. But what happens if millions of people (reluctantly) get the first injection, experience flu-like side effects, and then simply don’t return for the second?
Both Moderna’s and Pfizer’s vaccines requires a 2nd injection several weeks after the first in order to achieve immunity. But what happens if millions of people (reluctantly) get the first injection, experience flu-like side effects, and then simply don’t return for the second?
Researchers at SUNY Buffalo just published a paper highlighting the importance of mucosal immunity in determining effectiveness of Covid-19 vaccines.

This type of immunity can likely only be achieved by intranasal vaccines like $ALT and oral vaccines like $VXRT
Researchers at SUNY Buffalo just published a paper highlighting the importance of mucosal immunity in determining effectiveness of Covid-19 vaccines. This type of immunity can likely only be achieved by intranasal vaccines like $ALT and oral vaccines like $VXRT
Researchers at SUNY Buffalo just published a paper highlighting the importance of mucosal immunity in determining effectiveness of Covid-19 vaccines. This type of immunity can likely only be achieved by intranasal vaccines like $ALT and oral vaccines like $VXRT
Researchers at SUNY Buffalo just published a paper highlighting the importance of mucosal immunity in determining effectiveness of Covid-19 vaccines. This type of immunity can likely only be achieved by intranasal vaccines like $ALT and oral vaccines like $VXRT
Researchers at SUNY Buffalo just published a paper highlighting the importance of mucosal immunity in determining effectiveness of Covid-19 vaccines. This type of immunity can likely only be achieved by intranasal vaccines like $ALT and oral vaccines like $VXRT
Last night $VXRT quietly updated their hiring page to add 5 more manufacturing positions related to their oral vaccine. Not only is this a good sign that their Phase 1 trial is going well, but it’s very likely they have secured large-scale funding for accelerated development.
Last night $VXRT quietly updated their hiring page to add 5 more manufacturing positions related to their oral vaccine. Not only is this a good sign that their Phase 1 trial is going well, but it’s very likely they have secured large-scale funding for accelerated development.
Last night $VXRT quietly updated their hiring page to add 5 more manufacturing positions related to their oral vaccine. Not only is this a good sign that their Phase 1 trial is going well, but it’s very likely they have secured large-scale funding for accelerated development.
Last night $VXRT quietly updated their hiring page to add 5 more manufacturing positions related to their oral vaccine. Not only is this a good sign that their Phase 1 trial is going well, but it’s very likely they have secured large-scale funding for accelerated development.
$VXRT also just updated their progress on their universal flu vaccine (with Johnson and Johnson and Janssen), which now is apparently ready to begin Phase 1 trials. If it works, this vaccine tablet could protect you against influenza for decades, rather than a single year.
$VXRT also just updated their progress on their universal flu vaccine (with Johnson and Johnson and Janssen), which now is apparently ready to begin Phase 1 trials. If it works, this vaccine tablet could protect you against influenza for decades, rather than a single year.
$VXRT also just updated their progress on their universal flu vaccine (with Johnson and Johnson and Janssen), which now is apparently ready to begin Phase 1 trials. If it works, this vaccine tablet could protect you against influenza for decades, rather than a single year.
This article from the University of Antwerp about cold chain logistics is a stark reminder of why injectable vaccines are so difficult to transport. Apparently there are only 4 airports in all of Africa that can safely store these vaccines at the recommended temperatures.

$VXRT
This article from the University of Antwerp about cold chain logistics is a stark reminder of why injectable vaccines are so difficult to transport. Apparently there are only 4 airports in all of Africa that can safely store these vaccines at the recommended temperatures. $VXRT
This article from the University of Antwerp about cold chain logistics is a stark reminder of why injectable vaccines are so difficult to transport. Apparently there are only 4 airports in all of Africa that can safely store these vaccines at the recommended temperatures. $VXRT
$VXRT just added 5 MORE open positions to their hiring page, mostly related to vaccine manufacturing.

They also posted on their LinkedIn page claiming to be the “holy grail” oral vaccine that Operation Warp Speed director Moncef Slaoui mentioned last week.

This is very big.
$VXRT just added 5 MORE open positions to their hiring page, mostly related to vaccine manufacturing. They also posted on their LinkedIn page claiming to be the “holy grail” oral vaccine that Operation Warp Speed director Moncef Slaoui mentioned last week. This is very big.
$VXRT just added 5 MORE open positions to their hiring page, mostly related to vaccine manufacturing. They also posted on their LinkedIn page claiming to be the “holy grail” oral vaccine that Operation Warp Speed director Moncef Slaoui mentioned last week. This is very big.
$VXRT just added 5 MORE open positions to their hiring page, mostly related to vaccine manufacturing. They also posted on their LinkedIn page claiming to be the “holy grail” oral vaccine that Operation Warp Speed director Moncef Slaoui mentioned last week. This is very big.
All of this hiring news comes on the heels of $VXRT leasing out 24,000 (!) sq ft of laboratory and office space in South San Francisco (which shares a sky bridge with Johnson and Johnson 🤔) and a large vaccine manufacturing facility 5 miles south.

Now this is getting exciting.
All of this hiring news comes on the heels of $VXRT leasing out 24,000 (!) sq ft of laboratory and office space in South San Francisco (which shares a sky bridge with Johnson and Johnson ) and a large vaccine manufacturing facility 5 miles south.Now this is getting exciting.
All of this hiring news comes on the heels of $VXRT leasing out 24,000 (!) sq ft of laboratory and office space in South San Francisco (which shares a sky bridge with Johnson and Johnson ) and a large vaccine manufacturing facility 5 miles south.Now this is getting exciting.
All of this hiring news comes on the heels of $VXRT leasing out 24,000 (!) sq ft of laboratory and office space in South San Francisco (which shares a sky bridge with Johnson and Johnson ) and a large vaccine manufacturing facility 5 miles south.Now this is getting exciting.
All of this hiring news comes on the heels of $VXRT leasing out 24,000 (!) sq ft of laboratory and office space in South San Francisco (which shares a sky bridge with Johnson and Johnson ) and a large vaccine manufacturing facility 5 miles south.Now this is getting exciting.
This is about to be very big news and rage bait for people who are sick of wearing masks:

Because the injectable vaccines may only prevent symptoms but not contagion, masks will still be necessary.

That is, until an oral or nasal vaccine can produce mucosal immunity. $VXRT
This is about to be very big news and rage bait for people who are sick of wearing masks:Because the injectable vaccines may only prevent symptoms but not contagion, masks will still be necessary. That is, until an oral or nasal vaccine can produce mucosal immunity. $VXRT
This is about to be very big news and rage bait for people who are sick of wearing masks:Because the injectable vaccines may only prevent symptoms but not contagion, masks will still be necessary. That is, until an oral or nasal vaccine can produce mucosal immunity. $VXRT
This is about to be very big news and rage bait for people who are sick of wearing masks:Because the injectable vaccines may only prevent symptoms but not contagion, masks will still be necessary. That is, until an oral or nasal vaccine can produce mucosal immunity. $VXRT
This is about to be very big news and rage bait for people who are sick of wearing masks:Because the injectable vaccines may only prevent symptoms but not contagion, masks will still be necessary. That is, until an oral or nasal vaccine can produce mucosal immunity. $VXRT
A peer reviewed report just showed that the Pfizer vaccine is only 52% effective after the first injection.

That, coupled with the news that it is known to cause significant flu-like symptoms, is a recipe for disaster.

How many people will just “forget” to get the second shot?
A peer reviewed report just showed that the Pfizer vaccine is only 52% effective after the first injection.That, coupled with the news that it is known to cause significant flu-like symptoms, is a recipe for disaster. How many people will just “forget” to get the second shot?
A peer reviewed report just showed that the Pfizer vaccine is only 52% effective after the first injection.That, coupled with the news that it is known to cause significant flu-like symptoms, is a recipe for disaster. How many people will just “forget” to get the second shot?
A peer reviewed report just showed that the Pfizer vaccine is only 52% effective after the first injection.That, coupled with the news that it is known to cause significant flu-like symptoms, is a recipe for disaster. How many people will just “forget” to get the second shot?
Last week we learned that Vaxart is currently negotiating agreements with India and Mexico for its oral vaccine and this morning we just learned that they now have an official distribution agreement in Malaysia, population 23 million.

$VXRT
Last week we learned that Vaxart is currently negotiating agreements with India and Mexico for its oral vaccine and this morning we just learned that they now have an official distribution agreement in Malaysia, population 23 million. $VXRT
Last week we learned that Vaxart is currently negotiating agreements with India and Mexico for its oral vaccine and this morning we just learned that they now have an official distribution agreement in Malaysia, population 23 million. $VXRT
Apparently Vaxart just hired a lobbyist named Jeff Ricchetti, whose brother will be the top White House counselor to President elect Joe Biden 👀

$VXRT
As headlines about Pfizer’s vaccine shortages start to pile up, it’s worth remembering that Vaxart already has a manufacturing agreement with Atwill Medical Solutions to produce “a billion or more doses per year” of their oral vaccine.

You read that right — one BILLION.

$VXRT
As headlines about Pfizer’s vaccine shortages start to pile up, it’s worth remembering that Vaxart already has a manufacturing agreement with Atwill Medical Solutions to produce “a billion or more doses per year” of their oral vaccine. You read that right — one BILLION. $VXRT
As headlines about Pfizer’s vaccine shortages start to pile up, it’s worth remembering that Vaxart already has a manufacturing agreement with Atwill Medical Solutions to produce “a billion or more doses per year” of their oral vaccine. You read that right — one BILLION. $VXRT
As headlines about Pfizer’s vaccine shortages start to pile up, it’s worth remembering that Vaxart already has a manufacturing agreement with Atwill Medical Solutions to produce “a billion or more doses per year” of their oral vaccine. You read that right — one BILLION. $VXRT
Some bleak news coming out of the UK this week:

Scientists have discovered that a new faster-spreading mutation of the virus’ spike protein, which nearly every frontrunner vaccine has been designed to target.

The UK is now going on complete lockdown.
Some bleak news coming out of the UK this week: Scientists have discovered that a new faster-spreading mutation of the virus’ spike protein, which nearly every frontrunner vaccine has been designed to target. The UK is now going on complete lockdown.
Some bleak news coming out of the UK this week: Scientists have discovered that a new faster-spreading mutation of the virus’ spike protein, which nearly every frontrunner vaccine has been designed to target. The UK is now going on complete lockdown.
Though this is the not the first mutation of the virus’ spike protein, this one — called a “deletion” — is more significant and may cause complications with the vaccines’ ability to target it effectively.
Though this is the not the first mutation of the virus’ spike protein, this one — called a “deletion” — is more significant and may cause complications with the vaccines’ ability to target it effectively.
Though this is the not the first mutation of the virus’ spike protein, this one — called a “deletion” — is more significant and may cause complications with the vaccines’ ability to target it effectively.
Though this is the not the first mutation of the virus’ spike protein, this one — called a “deletion” — is more significant and may cause complications with the vaccines’ ability to target it effectively.
Though this is the not the first mutation of the virus’ spike protein, this one — called a “deletion” — is more significant and may cause complications with the vaccines’ ability to target it effectively.
Last month researchers published a study demonstrating how these deletion mutations could lead to “antigenic drift” — AKA a reduced ability for antibodies (and by extension, vaccines) to effectively target the virus’ spike protein.

https://www.biorxiv.org/content/10.1101/2020.11.19.389916v1
Last month researchers published a study demonstrating how these deletion mutations could lead to “antigenic drift” — AKA a reduced ability for antibodies (and by extension, vaccines) to effectively target the virus’ spike protein. https://www.biorxiv.org/content/10.1101/2020.11.19.389916v1
Last month researchers published a study demonstrating how these deletion mutations could lead to “antigenic drift” — AKA a reduced ability for antibodies (and by extension, vaccines) to effectively target the virus’ spike protein. https://www.biorxiv.org/content/10.1101/2020.11.19.389916v1
Though we all hope that these mutations are not serious enough to evade the new vaccines, it’s hopeful to note that companies like Vaxart were preparing for these inevitabilities and designed their vaccine to target both the spike (S) AND the more stable nucleocapsid (N) protein.
Though we all hope that these mutations are not serious enough to evade the new vaccines, it’s hopeful to note that companies like Vaxart were preparing for these inevitabilities and designed their vaccine to target both the spike (S) AND the more stable nucleocapsid (N) protein.
Though we all hope that these mutations are not serious enough to evade the new vaccines, it’s hopeful to note that companies like Vaxart were preparing for these inevitabilities and designed their vaccine to target both the spike (S) AND the more stable nucleocapsid (N) protein.
Though we all hope that these mutations are not serious enough to evade the new vaccines, it’s hopeful to note that companies like Vaxart were preparing for these inevitabilities and designed their vaccine to target both the spike (S) AND the more stable nucleocapsid (N) protein.
Though we all hope that these mutations are not serious enough to evade the new vaccines, it’s hopeful to note that companies like Vaxart were preparing for these inevitabilities and designed their vaccine to target both the spike (S) AND the more stable nucleocapsid (N) protein.
Vaxart’s CSO just shared some exciting details on a bio podcast:

1. P1 trial is complete, no serious adverse events, well tolerated; now reviewing immune data.

2. Tablets are Advil-sized, very cheap and quick to mass produce.

3. Hinted at possibility of a combined P2/3 trial.
Vaxart’s CSO just shared some exciting details on a bio podcast:1. P1 trial is complete, no serious adverse events, well tolerated; now reviewing immune data.2. Tablets are Advil-sized, very cheap and quick to mass produce.3. Hinted at possibility of a combined P2/3 trial.
Vaxart’s CSO just shared some exciting details on a bio podcast:1. P1 trial is complete, no serious adverse events, well tolerated; now reviewing immune data.2. Tablets are Advil-sized, very cheap and quick to mass produce.3. Hinted at possibility of a combined P2/3 trial.
Vaxart’s CSO just shared some exciting details on a bio podcast:1. P1 trial is complete, no serious adverse events, well tolerated; now reviewing immune data.2. Tablets are Advil-sized, very cheap and quick to mass produce.3. Hinted at possibility of a combined P2/3 trial.
Wow.

On February 3rd, Sean Tucker will be giving a presentation on Vaxart’s Phase 1 results at a conference alongside Anthony Fauci, Moncef Slaoui, and representatives from every other company selected for Operation Warp Speed.

Here we go...
Wow. On February 3rd, Sean Tucker will be giving a presentation on Vaxart’s Phase 1 results at a conference alongside Anthony Fauci, Moncef Slaoui, and representatives from every other company selected for Operation Warp Speed. Here we go...
Wow. On February 3rd, Sean Tucker will be giving a presentation on Vaxart’s Phase 1 results at a conference alongside Anthony Fauci, Moncef Slaoui, and representatives from every other company selected for Operation Warp Speed. Here we go...
Wow. On February 3rd, Sean Tucker will be giving a presentation on Vaxart’s Phase 1 results at a conference alongside Anthony Fauci, Moncef Slaoui, and representatives from every other company selected for Operation Warp Speed. Here we go...
You can follow @DrReynoldsChi.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.